HUP0401777A3 - 3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds - Google Patents

3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds

Info

Publication number
HUP0401777A3
HUP0401777A3 HU0401777A HUP0401777A HUP0401777A3 HU P0401777 A3 HUP0401777 A3 HU P0401777A3 HU 0401777 A HU0401777 A HU 0401777A HU P0401777 A HUP0401777 A HU P0401777A HU P0401777 A3 HUP0401777 A3 HU P0401777A3
Authority
HU
Hungary
Prior art keywords
purin
triazolo
adenosine
amines
compounds
Prior art date
Application number
HU0401777A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HUP0401777A2 publication Critical patent/HUP0401777A2/hu
Publication of HUP0401777A3 publication Critical patent/HUP0401777A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HU0401777A 2001-10-15 2002-10-11 3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds HUP0401777A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32956701P 2001-10-15 2001-10-15
PCT/US2002/032630 WO2003032996A1 (en) 2001-10-15 2002-10-11 Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists

Publications (2)

Publication Number Publication Date
HUP0401777A2 HUP0401777A2 (hu) 2004-12-28
HUP0401777A3 true HUP0401777A3 (en) 2008-06-30

Family

ID=23286007

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401777A HUP0401777A3 (en) 2001-10-15 2002-10-11 3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds

Country Status (16)

Country Link
US (1) US6653315B2 (enExample)
EP (1) EP1435960B1 (enExample)
JP (2) JP4545437B2 (enExample)
KR (1) KR100687954B1 (enExample)
CN (1) CN100421663C (enExample)
AR (1) AR037243A1 (enExample)
AU (1) AU2002340184B2 (enExample)
CA (1) CA2463598C (enExample)
HU (1) HUP0401777A3 (enExample)
IL (1) IL160878A0 (enExample)
MX (1) MXPA04003474A (enExample)
MY (1) MY124864A (enExample)
NZ (1) NZ531761A (enExample)
PE (1) PE20030477A1 (enExample)
WO (1) WO2003032996A1 (enExample)
ZA (1) ZA200402812B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005158A (es) * 2001-11-30 2004-08-11 Schering Corp Antagonistas receptores de adenosina a2a biciclica de (1.2.4]- triazol.
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
DE60335294D1 (de) 2002-12-19 2011-01-20 Schering Corp Dlung des extrapyramidalen syndroms
NZ542823A (en) 2003-04-23 2009-03-31 Schering Corp 2-Alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
CN1787821A (zh) * 2003-06-10 2006-06-14 协和发酵工业株式会社 一种治疗焦虑症的方法
MXPA06007102A (es) * 2003-12-19 2006-08-23 Schering Corp Composiciones farmaceuticas.
NZ550591A (en) 2004-04-21 2010-10-29 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2A receptor antagonists
ES2385702T3 (es) 2005-06-07 2012-07-30 Kyowa Hakko Kirin Co., Ltd. Antagonistas de A2A para uso en el tratamiento de trastornos de la motricidad
AR057817A1 (es) * 2005-09-19 2007-12-19 Schering Corp Antagonistas del receptor a2a de 2-heteroaril-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidin adenosina. composiciones farmaceuticas
AR056080A1 (es) * 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
WO2008045272A2 (en) * 2006-10-06 2008-04-17 Dynamis Therapeutics, Inc. Compositions and methods for skin lightening
EP2125750B1 (en) * 2007-02-26 2014-05-21 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US7691869B2 (en) * 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
JP5470557B2 (ja) * 2007-07-26 2014-04-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
US8440658B2 (en) 2007-12-11 2013-05-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
WO2009102428A2 (en) * 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
CA2715290A1 (en) * 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
EP2274287B1 (en) * 2008-03-18 2016-03-09 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
TW201004945A (en) 2008-05-01 2010-02-01 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5301563B2 (ja) * 2008-05-01 2013-09-25 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
EP2291373B1 (en) * 2008-05-01 2013-09-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8592410B2 (en) 2008-05-01 2013-11-26 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1
WO2010127237A2 (en) * 2009-04-30 2010-11-04 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2729998A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5379160B2 (ja) 2008-07-25 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
MA33216B1 (fr) 2009-04-30 2012-04-02 Boehringer Ingelheim Int Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
EP2448928B1 (en) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
EP2585444B1 (en) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
JP5843869B2 (ja) * 2010-09-24 2016-01-13 アドヴィナス・セラピューティックス・リミテッド アデノシン受容体拮抗薬としての縮合三環化合物
WO2012059416A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
WO2015027431A1 (en) * 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
EP3883576B1 (en) 2018-11-20 2025-12-17 Merck Sharp & Dohme LLC Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
CA3119774A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020112706A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
TW202039496A (zh) 2018-11-30 2020-11-01 美商默沙東藥廠 做為腺苷受體拮抗劑之9-經取代胺基三唑喹唑啉衍生物、醫藥組合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3677445D1 (de) 1985-09-30 1991-03-14 Ciba Geigy Ag 2-substituierte-e-kondensierte(1,5-c)-pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
EP0263071B1 (en) * 1986-09-30 1992-08-12 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4]-triazolo[1,5-c] pyrimidines, pharmaceutical compositions, and uses thereof
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
AU7237294A (en) * 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) * 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
CA2326716C (en) 1998-04-03 2006-12-12 Otsuka Pharmaceutical Factory, Inc. Triazolopurine derivative, pharmaceutical composition containing the derivative, adenosine a3 receptor ligand, and remedy for asthma
CA2385865A1 (en) 1999-09-28 2001-04-05 Takashi Okamura Triazolopurine derivatives, pharmaceutical compositions containing the derivatives, and adenosine a3 receptor affinitive agents
EP1283839B1 (en) 2000-05-26 2005-04-20 Schering Corporation Adenosine a2a receptor antagonists
JP4284182B2 (ja) 2001-11-30 2009-06-24 シェーリング コーポレイション アデノシンＡ２ａレセプターアンタゴニスト

Also Published As

Publication number Publication date
AU2002340184B2 (en) 2005-10-06
MXPA04003474A (es) 2004-07-30
HUP0401777A2 (hu) 2004-12-28
KR20050035155A (ko) 2005-04-15
ZA200402812B (en) 2005-04-25
IL160878A0 (en) 2004-08-31
KR100687954B1 (ko) 2007-02-27
JP2008297312A (ja) 2008-12-11
JP2005506352A (ja) 2005-03-03
CA2463598A1 (en) 2003-04-24
AR037243A1 (es) 2004-11-03
EP1435960B1 (en) 2014-07-30
PE20030477A1 (es) 2003-06-06
WO2003032996A1 (en) 2003-04-24
CA2463598C (en) 2009-09-08
JP4545437B2 (ja) 2010-09-15
CN1612736A (zh) 2005-05-04
CN100421663C (zh) 2008-10-01
US20030171381A1 (en) 2003-09-11
MY124864A (en) 2006-07-31
NZ531761A (en) 2005-10-28
EP1435960A1 (en) 2004-07-14
US6653315B2 (en) 2003-11-25

Similar Documents

Publication Publication Date Title
HUP0401777A3 (en) 3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds
HUP0402270A3 (en) [1,2,4]triazolo[1,5-c]pyrimidin-5-yl-amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing them
HUP0202810A3 (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands, process for their preparation and pharmaceutical compositions containing them
HUP0401047A3 (en) Triazolo[4,5-d]pyrimidine derivatives, their use as purinergic receptor antagonist and pharmaceutical compositions containing same
HUP0401301A3 (en) Pyrrolo pyrimidines, process for their preparation, their use and pharmaceutical compositions containing them
HUP0500107A3 (en) 1-alkyl-1-azoniabicyclo[2.2.2.]octane carbamate derivatives, pharmaceutical compositions comprising thereof and their use as muscarinic receptor antagonists
HUP0200308A2 (en) Quinolinecarboxamides as antiviral agents, pharmaceutical compositions containing them and their use
HUP0402018A3 (en) 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
HUP0301114A3 (en) Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them
HUP0401718A3 (en) Bicyclic oxopyridine and oxopyrimidine derivatives, their use and pharmaceutical compositions containing them
HUP0303148A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing the compounds and processes for their preparation
IL191960A (en) History of imidazo [5,1– a] pyridine and pharmaceutical preparations containing them
HUP0304082A3 (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203503A3 (en) Pyrrolo[2,3-d]pirimidine compounds, pharmaceutical compositions containing them and their use
IL158784A (en) Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives, processes for their preparation and pharmaceutical compositions containing them
HUP0400784A3 (en) Bicyclic heterocondensated pyrrolcarboxamide derivatives, their use and pharmaceutical compositions containing them
HUP0102453A3 (en) Adenosine derivatives, their use and pharmaceutical compositions containing the compounds
HUP0400692A3 (en) Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them
IL165977A (en) Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
HUP0401109A3 (en) Nociceptin analogs, their use and pharmaceutical compositions containing them
IL176005A0 (en) 2,6-bisheteroaryl-4-aminopyrimidine derivatives and pharmaceutical compositions containing the same
HUP0203836A3 (en) 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use
IL162185A0 (en) Phenylpropionate derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
HUP0401987A3 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
HUP0401638A3 (en) Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees